ScholarIQanswers from OpenAlex

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine

PaperCitations, authors & open-access status

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine have?

ScholarIQcitation count

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine has 9 citations in the OpenAlex counts ScholarIQ stores.

When was Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine published?

ScholarIQyear

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine has 2023 year in the ScholarIQ index.

What is the open-access status of Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine?

ScholarIQoa status

Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine has gold oa status in the ScholarIQ index.

What is the DOI of Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine?

ScholarIQdoi

The DOI for Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine is on the source record.

What is the PMID of Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine?

ScholarIQpmid

The PMID for Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine is on the source record.

What is the OpenAlex record for Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine?

ScholarIQopenalex

The OpenAlex for Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial